Evidence map›Paper›PMID 42678632›Full record

SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026

Smoking and disability outcomes in multiple sclerosis: a systematic review and meta-analysis.

Bassel Alrabadi, Yousef Alghzawi, Alwaleed Emad Alshakhshir, Natalie Bandak, Hasan I Matar, Aseel Badwan, Govind Mann, Ahmed Z Obeidat

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bassel AlrabadiFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan. bealrabadi22@med.just.edu.jo.ORCID http://orcid.org/0009-0007-1115-4610
Yousef AlghzawiFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Alwaleed Emad AlshakhshirFaculty of Medicine, Aqaba Medical Sciences University, Aqaba, Jordan.
Natalie BandakFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Hasan I MatarFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Aseel BadwanFaculty of Medicine, University of Jordan, Amman, Jordan.
Govind MannDepartment of Neurology, University of Kansas Medical Center, Kansas City, USA.
Ahmed Z ObeidatDepartment of Neurology, The Medical College of Wisconsin, Milwaukee, WI, 53226, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSmoking is a well-established environmental risk factor for multiple sclerosis (MS), yet its impact on disability progression remains incompletely understood, with conflicting evidence across studies.

objectiveThis review evaluated smoking and clinical outcomes in MS. Disability progression was the primary outcome; disability severity, imaging, relapse recovery, functional status, and patient-reported outcomes were secondary outcomes.

methodsA systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. PubMed, Scopus, Web of Science, and the Cochrane Library were searched from inception through the 4th of March 2026.

resultsEighteen studies were included. Smoking was not significantly associated with increased EDSS (SMD = 0.09, 95% CI [-0.04; 0.22]) or MSSS (SMD = 0.10, 95% CI [-0.15; 0.36]). Similarly, no significant associations were observed for progression to EDSS ≥4 (HR = 1.27, 95% CI [0.90; 1.81]) or EDSS ≥6 (HR = 1.20, 95% CI [0.65; 2.23]). T2 lesion volume was not significantly associated with smoking under the prespecified random-effects model. Broadly defined disability progression was not significantly associated with smoking, although the estimate was imprecise and heterogeneity was substantial (HR = 1.88, 95% CI [0.82; 4.32]). High heterogeneity was observed across several outcomes. Narrative findings suggested possible associations with poorer quality of life, greater fatigue, respiratory symptoms, and poorer relapse recovery, although these outcomes were heterogeneous and were not direct measures of longitudinal disability progression.

conclusionSmoking was generally associated with trends toward worse clinical outcomes in multiple sclerosis; however, statistically significant effects were not consistently observed across pooled analysis.

Indexed as

Disease ProgressionMultiple SclerosisSmokingDisability EvaluationHumansDisability progressionDisease severityEDSSMultiple sclerosisSmoking

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.